Wegovy lowers hospitalization risk for adults with obesity, established CVD

Once-weekly subcutaneous semaglutide 2.4 mg reduced the risk for any hospitalization among adults with obesity and established cardiovascular disease, according to an analysis of the SELECT trial published in JAMA Cardiology.
“The benefits of semaglutide (Wegovy, Novo Nordisk) in the SELECT trial extend far beyond the reduction in CV events that were previously reported,” Stephen J. Nicholls, MBBS, PhD, professor of cardiology and director of Victorian Heart Institute at Monash University in Melbourne, Australia, told Healio. “We observed a reduction in hospital admissions for a range of





